Friday, September 22, 2023
| Characteristic | No. (%) | |||
|---|---|---|---|---|
| Congenital syphilis (n = 360) | Noncongenital syphilis (n = 410) | |||
| Any substance use (n = 173) |
No substance use (n = 187) |
Any substance use (n = 101) |
No substance use (n = 309) |
|
| Age, yrs, median (IQR) | 27.7 (23.4–31.9) | 26.3 (21.8–30.7) | 27.8 (23.8–31.3) | 25.3 (22.2–29.6) |
| Age group, yrs | ||||
| <25 | 55 (31.8) | 72 (38.5) | 37 (36.6) | 146 (47.2) |
| 25–29 | 59 (34.1) | 63 (33.7) | 31 (30.7) | 92 (29.8) |
| 30–34 | 37 (21.4) | 34 (18.2) | 25 (24.8) | 54 (17.5) |
| ≥35 | 21 (12.1) | 16 (8.6) | 8 (7.9) | 17 (5.5) |
| Missing/Not reported | 1 (0.6) | 2 (1.1) | 0 (—) | 0 (—) |
| Education level | ||||
| Less than high school | 51 (29.5) | 55 (29.4) | 30 (29.7) | 94 (30.4) |
| High school graduate or GED | 53 (30.6) | 50 (26.7) | 35 (34.7) | 113 (36.6) |
| Some college but no degree | 24 (13.9) | 35 (18.7) | 24 (23.8) | 59 (19.1) |
| College degree or more | 5 (2.9) | 23 (12.3) | 8 (7.9) | 22 (7.1) |
| Missing/Not reported | 40 (23.1) | 24 (12.8) | 4 (4.0) | 21 (6.8) |
| Insurance at delivery | ||||
| Public | 130 (75.1) | 91 (48.7) | 81 (80.2) | 164 (53.1) |
| Private | 12 (6.9) | 12 (6.4) | 6 (5.9) | 31 (10.0) |
| Other/None/Self-pay | 14 (8.1) | 10 (5.3) | 2 (2.0) | 12 (3.9) |
| Missing/Not reported | 17 (9.8) | 74 (39.6) | 12 (11.9) | 102 (33.0) |
| Prenatal care | ||||
| First/Second trimester | 78 (45.1) | 124 (66.3) | 79 (78.2) | 281 (90.9) |
| Third trimester | 26 (15.0) | 25 (13.4) | 13 (12.9) | 16 (5.2) |
| No care | 66 (38.2) | 35 (18.7) | 4 (4.0) | 3 (1.0) |
| Missing/Not reported | 3 (1.7) | 3 (1.6) | 5 (5.0) | 9 (2.9) |
| No. of prenatal visits, median (IQR) | 1 (0–6) | 6 (1–10) | 9 (6–11) | 10 (7–13) |
| Treatment | ||||
| Adequate§ | 26 (15.0) | 46 (24.6) | 101 (100) | 309 (100) |
| Inadequate¶ | 55 (31.8) | 62 (33.2) | NA | NA |
| Not treated during pregnancy¶ | 92 (53.2) | 79 (42.2) | NA | NA |
| History of incarceration** | ||||
| Yes | 28 (16.2) | 6 (3.2) | 11 (10.9) | 5 (1.6) |
| No | 70 (40.5) | 102 (54.5) | 63 (62.4) | 181 (58.6) |
| Missing/Not reported | 75 (43.4) | 79 (42.2) | 27 (26.7) | 123 (39.8) |
| History of homelessness** | ||||
| Yes | 46 (26.6) | 2 (1.1) | 9 (8.9) | 3 (1.0) |
| No | 70 (40.5) | 106 (56.7) | 71 (70.3) | 190 (61.5) |
| Missing/Not reported | 57 (32.9) | 79 (42.2) | 21 (20.8) | 116 (37.5) |
Table 1. Characteristics of pregnant persons with syphilis, by reported substance use* and congenital syphilis pregnancy outcome† (N = 770) — Surveillance for Emerging Threats to Pregnant People and Infants Network, Arizona and Georgia, 2018–2021
Abbreviations: CSTE = Council of State and Territorial Epidemiologists; GED = general educational development certificate; NA = not applicable.
*Any substance use includes any use of tobacco (e.g., cigars, cigarettes, smokeless tobacco, or e-cigarettes), alcohol, cannabis, illicit use of opioids (e.g., prescription opioids not taken as prescribed, fentanyl, or heroin), and other illicit, nonprescription substances (e.g., cocaine, methamphetamines, inhalants, or hallucinogens, such as LSD or PCP).
†Congenital syphilis pregnancy outcome includes pregnancy outcomes that meet the CSTE surveillance case definition for syphilitic stillborn or live-born infant with probable or confirmed congenital syphilis.
§Adequacy of treatment dependent on syphilis stage. Primary, secondary, and early latent syphilis require at least 1 dose of penicillin during pregnancy, with the dose administered ≥30 days before pregnancy outcome. Late latent, latent of unknown duration, tertiary, and other cases of syphilis require ≥3 doses of penicillin, spaced 5–9 days apart, with the first dose administered ≥30 days before delivery and the final dose administered during pregnancy.
¶Stillborn and live-born infants born to pregnant persons inadequately treated or not treated during pregnancy meet the CSTE case definition for a probable congenital syphilis pregnancy outcome.
**Within the 12 months preceding case report or positive test results or during pregnancy.
| Substance used | No. (%) | Prevalence ratio¶
(95% CI) |
|
|---|---|---|---|
| Congenital syphilis (n = 360) |
Noncongenital syphilis (n = 410) |
||
| Any substance* | 173 (48.1) | 101 (24.6) | 1.95 (1.60–2.38) |
| Tobacco | 99 (27.5) | 46 (11.2)** | 2.45 (1.78–3.37) |
| Alcohol | 29 (8.1) | 20 (4.9)** | 1.65 (0.95–2.86) |
| Cannabis | 69 (19.2) | 56 (13.7)†† | 1.40 (1.01–1.93) |
| Illicit use of opioids§§ | 75 (20.8) | 14 (3.4)** | 6.09 (3.50–10.58) |
| Illicit, nonprescription substance¶¶ | 101 (28.1) | 26 (6.4)** | 4.41 (2.94–6.63) |
Table 2. Reported substance use*,† among pregnant persons with syphilis, by congenital syphilis pregnancy outcome§ — Surveillance for Emerging Threats to Pregnant People and Infants Network, Arizona and Georgia, 2018–2021
Abbreviation: CSTE = Council of State and Territorial Epidemiologists.
*Any substance use includes any use of tobacco (e.g., cigars, cigarettes, smokeless tobacco, or e-cigarettes), alcohol, cannabis, illicit use of opioids (e.g., prescription opioids not taken as prescribed, fentanyl, or heroin), and other illicit, nonprescription substances (e.g., cocaine, methamphetamines, inhalants, or hallucinogens such as LSD or PCP).
†Numbers in categories are not mutually exclusive.
§Congenital syphilis pregnancy outcome includes pregnancy outcomes that meet CSTE surveillance case definition for syphilitic stillborn and live-born infant with probable or confirmed congenital syphilis.
¶Unadjusted.
**Denominator = 409.
††Denominator = 408.
§§Includes prescription opioids not taken as prescribed, fentanyl, and heroin.
¶¶Includes other illicit, nonprescription substances (e.g., cocaine, methamphetamines, inhalants, or hallucinogens such as LSD or PCP).
Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™
ABIM Diplomates - maximum of 0.25 ABIM MOC points
Nurses - 0.25 ANCC Contact Hour(s) (0 contact hours are in the area of pharmacology)
Pharmacists - 0.25 Knowledge-based ACPE (0.025 CEUs)
This activity is intended for primary care clinicians, obstetricians, infectious disease specialists, and other healthcare professionals who care for women considering pregnancy.
The goal of this activity is for learners to be better able to analyze risk factors for congenital syphilis.
Upon completion of this activity, participants will:
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.
Awarded 0.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.00 contact hours are in the area of pharmacology.
Medscape designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) (Universal Activity Number: JA0007105-0000-23-306-H01-P).
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit(s)™, you must receive a minimum score of 75% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC / CE Released: 8/30/2023
Valid for credit through: 8/30/2024, 11:59 PM EST
processing....
Despite universal prenatal syphilis screening recommendations and availability of effective antibiotic treatment, syphilis prevalence during pregnancy and the incidence of congenital syphilis have continued to increase in the United States.[1,2] Concurrent increases in methamphetamine, injection drug, and heroin use have been described in women with syphilis.[3] CDC used data on births that occurred during January 1, 2018–December 31, 2021, from two states (Arizona and Georgia) that participate in the Surveillance for Emerging Threats to Pregnant People and Infants Network (SET-NET) to describe the prevalence of substance use among pregnant persons with syphilis by congenital syphilis pregnancy outcome (defined as delivery of a stillborn or live-born infant meeting the surveillance case definition for probable or confirmed congenital syphilis). The prevalence of substance use (e.g., tobacco, alcohol, cannabis, illicit use of opioids, and other illicit, nonprescription substances) in persons with a congenital syphilis pregnancy outcome (48.1%) was nearly double that among those with a noncongenital syphilis pregnancy outcome (24.6%). Persons with a congenital syphilis pregnancy outcome were six times as likely to report illicit use of opioids and four times as likely to report using other illicit, nonprescription substances during pregnancy than were persons with a noncongenital syphilis pregnancy outcome. Approximately one half of persons who used substances during pregnancy and had a congenital syphilis pregnancy outcome had late or no prenatal care. Tailored interventions should address barriers and facilitators to accessing screening and treatment for syphilis among persons who use substances. The need for syphilis screening and treatment should be addressed at any health care encounter during pregnancy, especially among persons who use substances.
SET-NET is a longitudinal surveillance approach established to identify infectious exposures, including syphilis, during pregnancy and monitor health outcomes in pregnant persons and their infants.[4] In collaboration with CDC, Arizona and Georgia conducted enhanced surveillance for both syphilis in pregnancy and congenital syphilis based on case investigations, medical records, and linkage of laboratory results with vital records. Arizona focused surveillance efforts on Maricopa, Pima, and Yuma counties (approximately 80% of the state's births); Georgia's surveillance was statewide. Pregnancies were included if 1) the person met the Council of State and Territorial Epidemiologists (CSTE) case definition* for syphilis (all stages) at any point during pregnancy or 2) the person had a syphilitic stillborn or live-born infant or child who met the CSTE case definition for probable or confirmed congenital syphilis. Substance use during pregnancy, obtained from case investigation interviews or from medical records, included use of tobacco (e.g., cigars, cigarettes, smokeless tobacco, or e-cigarettes), alcohol, cannabis, illicit use of opioids (e.g., prescription opioids not taken as prescribed, fentanyl, or heroin), and other illicit, nonprescription substances (e.g., cocaine, methamphetamines, inhalants, or hallucinogens such as LSD or PCP).
Births that occurred during January 1, 2018–December 31, 2021,† and were reported to CDC as of September 9, 2022, were analyzed to compare the prevalence of any substance use among pregnant persons with syphilis by whether their pregnancy outcome met the surveillance case definition for probable or confirmed congenital syphilis§ (congenital syphilis pregnancy outcome) or did not (noncongenital syphilis pregnancy outcome) and to describe selected demographic, prenatal care, clinical and treatment information, and history of incarceration and homelessness in the 12 months preceding case report or positive test results or during pregnancy. All analyses were performed using R statistical software (version 4.1.2; R Foundation). This activity was reviewed by CDC and conducted consistent with applicable federal law and CDC policy.¶
Among 770 pregnant persons who met inclusion criteria (17 with multiple gestations), 360 (46.8%) had a congenital syphilis pregnancy outcome (Table 1). Among 309 persons with a noncongenital syphilis pregnancy outcome and who did not use substances, 47.2% were aged <25 years, compared with 31.8% of those with a congenital syphilis pregnancy outcome who used substances. The prevalence of other age groups was distributed similarly across congenital syphilis pregnancy outcome and substance use status.
Among persons with a congenital syphilis pregnancy outcome, 53.2% of those who used substances and 32.1% of those who did not use substances received late (third trimester) or no prenatal care. Among persons with a noncongenital syphilis pregnancy outcome, 16.8% of those who used a substance and 6.1% of those who did not use a substance received late or no prenatal care. Irrespective of congenital syphilis pregnancy outcome, 39.8% of persons who used substances during pregnancy (274) either did not receive prenatal care or received it in the third trimester compared with 15.9% for those without substance use during pregnancy (496). Persons who used substances had, on average, six prenatal care visits, and those without substance use had nine. Among persons who used substances during pregnancy, 38.2% of those with a congenital syphilis pregnancy outcome received no prenatal care, compared with 4.0% of those with a noncongenital syphilis pregnancy outcome.
Among persons with a congenital syphilis pregnancy outcome, adequate treatment was received by 15.0% of those who did use any substances during pregnancy and 24.6% who did not. More than one half (53.2%) of 173 persons with a congenital syphilis pregnancy outcome and who used substances received no treatment for syphilis during pregnancy, compared with 42.2% of 187 persons who did not use substances.
Among persons who used substances during pregnancy, 16.2% of persons with a congenital syphilis outcome and 10.9% of persons with a noncongenital syphilis outcome had a history of incarceration; for history of homelessness in these groups the frequency was 26.6% and 8.9%. Data on incarceration were missing or not reported for 39% of all persons included in this analysis. Data on homelessness were missing or not reported for 35% of all persons included in this analysis.
Persons with a congenital syphilis pregnancy outcome were almost twice as likely to have used any substance during pregnancy as were those without this outcome (48.1% versus 24.6%; prevalence ratio [PR] = 1.95) (Table 2). Illicit use of opioids and illicit, nonprescription substances were the substance uses most frequently associated with a congenital syphilis pregnancy outcome. Illicit use of opioids during pregnancy was six times higher (PR = 6.09) and use of other illicit, nonprescription substances was more than four times higher (PR = 4.41) among persons with a congenital syphilis pregnancy outcome compared with those with a noncongenital syphilis outcome.
*https://ndc.services.cdc.gov/case-definitions/syphilis-2018/
†For Arizona, a pregnant person's receipt of a positive syphilis test result and pregnancy outcome date occurred during 2019–2021. For Georgia, a pregnant person's receipt of a positive syphilis test result occurred during 2017–2019 and pregnancy outcome date during 2018–2019.
§Live-born infants were considered to have confirmed congenital syphilis if they met laboratory criteria for demonstration
of Treponema pallidum. Live-born infants were considered to have probable congenital syphilis if the pregnant person had untreated or inadequately
treated syphilis during pregnancy based on CDC treatment guidelines or if the infant received a reactive nontreponemal test
result for syphilis and any of the following: evidence of syphilis on physical examination (excluding jaundice alone after
2019), abnormalities identified on long bone radiographs, reactive cerebrospinal fluid (CSF) venereal disease research laboratory
test, or elevated CSF white blood cell counts or protein values. Stillborn infants were considered a syphilitic stillbirth
if the pregnant person had untreated or inadequately treated syphilis during pregnancy based on CDC treatment guidelines and
fetal death occurred after 20 weeks' gestation or the fetus weighed >1.1 lbs (>0.5 kg).
¶45 C.F.R. part 46.102(l)(2), 42 U.S.C. Sect. 241(d); 5 U.S.C. Sect. 552a.
